Navigation Links
Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
Date:8/19/2009

NOVATO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride) and Naglazyme(R) (galsulfase) will be presented at the 11th Annual Meeting of the International Congress of Inborn Errors of Metabolism (ICIEM) in San Diego, California, August 29 through September 2, 2009.

"We look forward to a number of abstracts, posters and platform presentations that will highlight a variety of topics on the treatment of PKU and MPS VI. In particular, results from the PKU studies will hopefully strengthen the safety and efficacy data for Kuvan and demonstrate both the broad use of the medicine across different patient populations as well as possible neurocognitive benefits," said Chief Medical Officer Hank Fuchs, M.D.

The following abstracts, posters and presentations will be featured:

Phenylketonuria (PKU)

#171: Sapropterin Dihydrochloride Response in 35 Patients with Hyperphenylalaninemia (Vernon, et al)

#179: Clinical Experience with KUVAN Therapy in Young Children with Phenylketonuria (PKU) (Mofidi, et al)

#185: An Outreach Program for Adults Living with PKU (Leviton and Burton)

#187: PKU Treatment with Tetrahydrobiopterin (Sapropterin) During Pregnancy (Cunningham, et al)

#192: Treatment of an Individual with Phenylketonuria and Neurological Impairment with Sapropterin (Adams)

#195: The KUVAN Adult Maternal Pediatric European Registry (KAMPER): A Long Term Observational Study of Patients with Hyperphenylalaninaemia Treated with KUVAN (Champigneulle, et al)

#202: Responsiveness of KUVAN in PKU Patients During the Expanded Access Program and Following FDA Approval (Bernstein, et al)

#205: Compliance in a Group of Adolescents and Adults with Phenylketonuria (Vilaseca, et al)

#208: Assessing Cognitive and Social-Emotional Functioning in Individuals with PKU: Tools for Use in the Metabolic Clinic by Psychologists and Non-Psychologists (Waisbren, et al)

#211: Revisiting Suboptimal Outcomes of Diet-Treated PKU Patients (Enns, et al)

#216: Neuropsychological Function in Individuals with Phenylketonuria Treated with KUVAN (Grange, et al)

#236: Factors that May Lead to Inappropriate Discontinuation of KUVAN After at Least 3 Months of Continued Therapy (Imperiale, et al)

#550: NBS Long-Term Follow-Up: Improving Outcome in PKU - Drug TX and Diet Liberalization (Adams, Adams)

#594: Sapropterin Dihydrochloride (6R-BH4) and Maternal Phenylketonuria: Two Case Studies (Moseley, et al)

#647: Assessment of the Effectiveness of Metabolic University: A Training Program for Registered Dietitians, Nurses, Genetic Counselors, and Physicians (Bernstein, et al)

Mucopolysaccharidosis VI (MPS VI)

#101: The First Report of the MPS VI Clinical Surveillance Program (CSP) (Hendriksz et al) Platform Presentation - Sunday, August 30, 16:00

#348: ERT in an MPS VI Patient who was previously treated with Bone Marrow Transplantation (Sohn et al)

#379: Enzyme Replacement Therapy in Eight Mucopolysaccharidosis Type VI Brazilian Children Under Age Three: Preliminary Data (Horovitz et al)

#400: Cholelithiasis in Two MPS VI Patients: Expanding the Phenotype of Maroteaux-Lamy Syndrome (Lourenco et al)

#402: Enzyme Replacement Therapy for MPS VI: Experience in Taiwan (Lin et al)

#405: Experience of Enzyme Replacement Therapy in Patients with Mucopolysaccharidosis Type VI (Micheletti et al)

#410: Mucopolysaccharidosis Type VI Diagnosis Using Dried Blood Spot Samples - A Brazilian Experience (Gimenes et al)

#413: Craniovertebral Abnormalities and Spinal Cord Compression in Type VI Mucopolysaccharidosis (Horovitz et al)

#423: Decompress Cervical Surgery in Patient with Advanced MPS VI (Solano et al)

#424: Sleep Evaluation in Patients with Mucopolysaccharidosis Type VI (Souza et al)

#426: Severe Cardiomyopathy is Reverted in Patient with Advanced MPS VI Under ERT (Solano et al)

#437: MPS VI - Report of a Very Mild Phenotype in a Brazilian Patient (Souza et al)

#441: High Prevalence of Mental Impairment in a Series of Six Patients with Mucopolysaccharidosis Type VI (Valayannopoulos et al)

#444: Treatment of Diarrhea in Patient with MPS - Cases Report (Frangipani et al)

#449: Phonological Assessment in Patient with MPS I, MPS II and MPS VI (Goncalves et al)

#464: Clinical Characterization and Follow up of 26 Colombian Patients with MPS VI (Solano et al)

#466: Prevalence of MPS VI Patients in Brazil (Martins et al)

#469: Maroteaux Lamy Syndrome: Enzyme Replacement Therapy Outcome in a Severe Form (Ospina et al)

#473: 20-Year Follow Up of Bone Marrow Transplantation in a MPS VI Patient with Substantial Residual Pathology (Andersson)

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About Kuvan

Kuvan(R) (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of orphan exclusivity in the United States and ten years of market exclusivity in the E.U.

About MPS VI

MPS VI (also known as Maroteaux-Lamy syndrome) is a debilitating, life-threatening genetic disease caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase. This enzyme deficiency leads to the accumulation of certain complex carbohydrates, glycosaminoglycans (GAGs), in the lysosomes, giving rise to progressive cellular, tissue and organ system dysfunction. The majority of individuals with MPS VI die from disease-related complications between childhood and early adulthood. Additional information can be found at www.mpsvi.com.

About Naglazyme

Naglazyme(R) is the first and only enzyme replacement therapy indicated for the treatment of MPS VI. Naglazyme is indicated for patients with MPS VI. Naglazyme has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in Naglazyme-treated patients were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and otitis media. Severe reactions included angioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued for adverse events and all patients who completed the double-blind portion of the trial continued to receive weekly infusions of Naglazyme. Nearly all patients developed antibodies as a result of treatment, but the level of the immune response did not correlate with the severity of adverse events. Because antihistamine use may increase the risk of apneic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay Naglazyme infusion should be given when treating patients who present with an acute febrile or respiratory illness. Additional information can be found at www.naglazyme.com.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors                               Media
    Eugenia Shen                            Susan Berg
    BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
    (415) 506-6570                          (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
2. BioMarin Receives 2009 Corporate Award for the Development of Kuvan
3. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
4. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
5. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
6. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco
7. Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates
8. Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates
9. President Obama Presented With Startling Book The Art of Conscious Parenting by the American Foundation for Conscious Parenting
10. 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
11. Shoulder Surgery Doesn't Prevent Return to Sports, According to New Study presented at AOSSM Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology: